A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT04077723)
An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is divided into a dose-escalation stage (Part I and Part II) and a dose expansion stage (Part III).
Who can join: Review the eligibility criteria below.
Location: City of Hope Medical Center — Pasadena, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (35 Sites)
Showing the first 25 of 35 sites.
- City of Hope Medical Center — Pasadena, California
- University of California San Francisco — San Francisco, California
- Washington University School of Medicine — St Louis, Missouri
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Peter Maccallum Cancer Centre — Melbourne, Victoria
- The Alfred Hospital — Melbourne, Victoria
- UZ Gent — Ghent,
- Queen Elizabeth II Health Sciences Centre — Halifax, Nova Scotia
- Jewish General Hospital — Montreal, Quebec
- Beijing Cancer Hospital — Beijing,
- Shandong Cancer Hospital — Jinan,
- Fudan University Shanghai Cancer Center — Shanghai,
- The First Affiliated Hospital of Xiamen University — Xiamen,
- Aarhus Universitetshospital Skejby — Aarhus N,
- Rigshospitalet — København Ø,
- Odense Universitetshospital — Odense C,
- CHRU de Lille — Lille,
- CHU Montpellier - Saint ELOI — Montpellier,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
- CHU DE RENNES - CHU Pontchaillou — Rennes,
- Istituto Nazionale Tumori Irccs Fondazione g. Pascale — Naples, Campania
- Asst Papa Giovanni Xxiii — Bergamo, Lombardy
- Irccs Istituto Europeo Di Oncologia (IEO) — Milan, Lombardy
- Istituto Clinico Humanitas — Rozzano, Lombardy
- Auckland City Hospital, Cancer and Blood Research — Auckland,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, Non-Hodgkin
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Denver, Colorado
- A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) — Duarte, California
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) — Santa Monica, California
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Duarte, California
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma — St Louis, Missouri
Explore by condition: All Lymphoma, Non-Hodgkin clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.